Inside the US Market: Expansion and Capital Raising for Australian Digital Health and Life Sciences Innovators

An exclusive networking function for founders, executives and investors in the Australian digital health and life sciences industry.

As the world’s largest health market, the US is a natural next step for many Australian digital health and life sciences companies. It is also one of the most competitive and expensive markets to enter, and US investors expect companies to arrive with the evidence, structure and plan to succeed there.

This exclusive session gives founders and senior leaders a practical view of what it takes to expand into the US and raise capital from US investors in the current climate. Hear from international guest speaker Lisa Suennen, Managing Partner of American Heart Association Ventures, on her latest US market insights drawn from more than 35 years as a leading investor, operator and adviser in US healthcare.

Lisa will join Bronwyn Le Grice (ANDHealth) and Dr Bob Soh (Brandon Capital) for a panel discussion on how Australian companies should sequence evidence, regulation and first customers, what US investors look for, and how Australian and US investors can work together on a raise.

Don’t miss this opportunity to gain valuable insights from one of health tech’s most influential people and connect with digital health and life sciences innovators over networking drinks.

EVENT DETAILS

Date: Wednesday 2 December 2026

Time: 4:00pm – 6:30pm (including networking drinks)

Where: ACMD Building, The Discovery Centre, Level 7, 27 Victoria Parade, Fitzroy VIC 3065

Speakers:

Lisa Suennen, Managing Partner, American Heart Association Ventures

Dr Bob Soh, Partner, Brandon Capital

Bronwyn Le Grice, Managing Director and CEO, ANDHealth

Session format: In-person (only) with presentation, panel, Q&A and networking

Registration: $45 for ANDHealth members and $75 for non-members

Who should attend:

• Founders and senior leaders of digital health and life sciences companies considering US expansion or US investment

• Commercial, regulatory and business development leads planning a US market entry

• Investors, advisers and service providers who support companies entering the US

This ANDHealth event is delivered in collaboration with Brandon BioCatalyst and hosted by CHICC.

MEET OUR SPEAKERS

Lisa Suennen, Managing Partner, American Heart Association Ventures

Lisa Suennen stands as one of the most influential figures in digital health and health technology investment, with a career spanning over 35 years at the intersection of healthcare, technology and venture capital. Renowned for her strategic vision, operational expertise and advocacy for innovation, she has played a pivotal role in shaping the digital health landscape globally.

Lisa is currently the Managing Partner at American Heart Association Ventures, where she oversees a platform of four venture funds investing across the healthcare spectrum. Her focus spans digital health, medical devices and solutions for cardiovascular and brain health, as well as broader determinants of health.

Previously, Lisa served as General Partner at Manatt Ventures, Psilos Group and GE Ventures. At GE Ventures, she directed the healthcare venture fund, evaluating thousands of pitches each year and making selective, high-impact investments in digital health, including AI-driven medical imaging, telemedicine and remote patient monitoring. At Psilos Group, she played a key role in early investments in companies such as Definity Health, ActiveHealth Management and Extend Health, all of which achieved significant exits, further establishing her as a leading healthcare investor.

Lisa’s investment philosophy centres on solutions that address real customer needs and navigate the complexities between patients, payers and providers. Named one of Business Insider’s nine digital health power players, she is widely recognised for her ability to bridge startups and large healthcare organisations. She has also been a critical architect in launching and scaling digital health initiatives such as the Go Red for Women Venture Fund and Cardeation Capital, pioneering disease-focused investment in the nonprofit sector.

Lisa chairs the International Investment Committee for Australia’s ANDHealth Digital Health Accelerator Fund, supporting early-stage digital health startups and international growth. She also led the Scientific Advisory Board for NASA’s Translational Research Institute for Space Health, demonstrating her commitment to advancing health innovation globally.

As Co-founder and CEO of CSweetener, Lisa created a mentorship platform for rising healthcare leaders, later acquired by the HLTH Foundation. She is a leading advocate for women in health tech, providing mentorship, writing on industry challenges and hosting podcasts to amplify female entrepreneurs’ voices.

Lisa is a Fellow of the Aspen Institute’s Health Innovators Fellowship and teaches healthcare innovation and investment at UC Berkeley Haas School of Business. She authors the widely read Venture Valkyrie blog and is an internationally recognised speaker and author on digital health and investment trends.

Dr Bob Soh, Partner, Brandon Capital

Prior to joining Brandon Capital, Bob was Deputy Chief Medical Officer at Nucleus Network, Australia’s largest clinical trials unit. He was involved in overseeing and executing over 100 early phase clinical trials, including as Principal Investigator. He was also involved in overseeing Nucleus Network’s clinical operations, business development and expanding its trial capabilities.

During his time at Nucleus Network, he was appointed as the founding executive for Cardiora, a Brandon Capital investee company developing therapies for heart failure. He successfully led Cardiora through multiple phase 2 clinical trials. The program was subsequently licensed to a specialty pharmaceutical company.

Bob obtained his MD from The University of Melbourne and subsequently undertook his surgical residency in some of Australia’s leading academic hospitals, including the Royal Melbourne Hospital and Royal North Shore Hospital. He is a Graduate of the Australian Institute of Company Directors and currently lectures in the University of Melbourne’s MBA and Biodesign programs. Since joining Brandon, he has led investments both in Australia and in the US across therapeutic areas and also runs Brandon Capital’s training programs.

Bronwyn Le Grice, CEO and Managing Director, ANDHealth

Bronwyn has over 20 years executive experience in health technology commercialisation, venture capital, capital raising and industry advocacy. In 2017 she founded ANDHealth, an organisation that supports digital health companies in Australia by providing education, resources, non-dilutive funding and mentorship to help them navigate the complexities of the healthcare industry.

ANDHealth is now one of Australia’s leading health technology commercialisation organisations with companies participating in its flagship ANDHealth+ program raising $19.70 in new capital and generating $6.70 in new revenues for every dollar invested. ANDHealth manages over $30M in public and private commitments to digital health commercialisation, and provides specialist support to a further $100M of funding managed by Brandon Capital.

Bronwyn has been a Member of the Council of the National Health & Medical Research Council since 2021. She is also currently a Non-Executive Director of Lumos Diagnostics Ltd (ASX.LDX) alongside a number of other advisory roles.